Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014091
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 10
---
 61,889 |
| Other information                             |   |                  |     |   |                  |
| Operating cash flows used in operating leases |   |           70,080 |     |   |                - |
| Remaining lease term (in years)               |   |             1.92 |     |   |             2.92 |
| Discount rate                                 |   |              10% |     |   |              10% |

As of June 30, 2025, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:

| 2025                                              | $ | 144,365 |   |
| 2026                                              |   | 148,696 |   |
| 2027                                              |   |       - |   |
| Total future minimum lease payments, undiscounted |   | 293,061 |   |
| Present value discount                            |   | (26,906 | ) |
| Total lease liability                             | $ | 266,155 |   |

5. Share capital Authorized The Company has authorized an unlimited number of common shares participating, voting and without par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders. On October 28, 2024, the Company completed a reverse share split at the ratio of 1-for-2, resulting in 10,846,721 common shares after conversion. Conversion of convertible notes On May 3, 2024, the Company issued convertible notes in the principal amount of $5,172,500. The convertible notes accrued interest at the rate of 10% per annum, payable in-kind semi-annually in arrears in the form of either cash or common shares of the Company, at the election of the holder, and had a maturity date of December 31, 2025. Prior to January 1, 2025, the convertible notes would automatically convert to common shares in the event that the Company completed an initial public offering in the United States, at a conversion price equal to the greater of (i) a 20% discount to the initial public offering price and (ii) $4.00; or if there had been a change of control, at a conversion price of $4.00 per common share. On or after January 1, 2025, conversion would be at the option of the holder at a conversion price of $4.00 per common share. The Company